Himanshu Nagar, MD
Radiation Oncology · New York, NYNPI 1376868554
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (39.1%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Viewray Technologies Inc at 36.7% of the total. Among radiation oncology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 109 payments — averaging $390.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viewray Technologies Inc$16K
- Elekta, Inc.$9K
- Pfizer$6K
- Boston Scientific$4K
- Blue Earth Diagnostics$2K
- Telix Pharmaceuticals$2K
- plus $4K from 15 others
Across 5 payments — averaging $56,733 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Viewray Technologies Inc$242K
- Genentech, Inc.$41K
What the payments were for
- Consulting fees$12,92730%
- Speaking & faculty fees$16,65039%
- Travel & lodging$4,08710%
- Food & beverage$8,10219%
- Education$8002%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viewray Technologies Inc | 18 | $15,617 |
| Elekta, Inc. | 16 | $9,357 |
| Pfizer | 10 | $5,537 |
| Boston Scientific | 22 | $3,962 |
| Blue Earth Diagnostics | 5 | $2,336 |
| Telix Pharmaceuticals | 9 | $1,973 |
| Astellas Pharma US Inc | 1 | $1,650 |
| Angiodynamics, Inc. | 5 | $479 |
| Bayer | 3 | $290 |
| Progenics Pharmaceuticals, Inc. | 3 | $288 |
| Myovant Sciences Inc. | 4 | $212 |
| Siemens Medical Solutions USA, Inc. | 2 | $175 |
| Varian Medical Systems, Inc. | 1 | $142 |
| Palette Life Sciences, Inc. | 1 | $117 |
| Exelixis Inc. | 1 | $107 |
| Johnson & Johnson | 1 | $103 |
| Sanofi | 1 | $96 |
| EDAP Technomed Inc | 3 | $42 |
| GT Medical Technologies, Inc | 1 | $35 |
| Roche Diagnostics Corporation | 1 | $24 |
| Bioprotect Medical, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MRIdian$14,408
- XTANDI$6,810
- ELEKTA MEDICAL LINEAR ACCELERATOR$5,547
- ILLUCCIX$2,547
- POSLUMA$2,259
- SpaceOAR VUE System - 10mL$2,012
- ELEKTA UNITY$1,826
- MRIdian LINAC$1,128
- SpaceOAR System$801
- GENERAL BPH$588
- ORGOVYX$561
- TALZENNA$435
- PYLARIFY$267
- Halcyon$142
- GENERAL - THERAPIES$116
- Nanoknife$115
- Varian Ethos Treatment Planning$115
- GreenLight XPS$109
- Cabometyx$107
- Erleada$103
How this compares
$42,566 in reported general payments places this provider in the 95th percentile of 397 radiation oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 12 | $8,139 |
| Tamsulosin Hcl | 66 | $1,136 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $1,650 | $8,13912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 397 radiation oncology providers in New York.
Other radiation oncology in New York
- Michael ZelefskyNew York$946K
- Nancy LeeNew York$233K
- Robert SamsteinNew York$125K
- Jalal AhmedNew York$100K
- Charles SimoneNew York$84K
- Silvia FormentiNew York$57K
- Brandon ImberNew York$44K
- Chiaojung TsaiNew York$38K
- Christopher BarkerNew York$32K
- Yoshiya YamadaNew York$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.